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Single nucleotide variantDespite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical
value ofWGS in the cancer genetics clinic is unknown.We performedWGS onmembers of two cohorts of cancer
genetics patients: thosewith BRCA1/2mutations (n= 176) and thosewithout (n=82). Initial analysis of poten-
tially pathogenic variants (PPVs, deﬁned as nonsynonymous variants with allele frequency b 1% in ESP6500) in
163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact
that a majority of PPVs were novel missense variants likely to be classiﬁed as variants of unknown signiﬁcance
(VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their pre-
dicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to con-
solidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function
(LoF) variants represented only a small fraction of PPVs, WGS identiﬁed additional cancer risk LoF PPVs in pa-
tients with known BRCA1/2mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics pa-
tients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to
improve our ability to discover patients' cancer genetic risks.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
With the rapid development and decreasing cost of whole-genome
sequencing (WGS) technologies, this genetic testing tool will soon be
readily available for common use in the laboratory and clinic (Collins
and Hamburg, 2013). Though the research community is rejoicing in
the newfound ability to use WGS to investigate patients' genomes in
better detail, clinicians aremore cautious. The unknown, but potentially
signiﬁcant, burden of delivering genetic results of uncertain value to pa-
tients weighs heavily on practitioners, such as oncologists, cardiologists
and neurologists.
WGS, and whole-exome sequencing, have already been used to pro-
vide genetic diagnoses that inform clinical care (Worthey et al., 2011;
Bainbridge et al., 2011; Rios et al., 2010). These early successes inas, TX 75390, USA.
oss).
. This is an open access article underindividual patients prompted expanded studies to investigate a more
general use of WGS in clinical settings (Saunders et al., 2012). Indeed
the growing adoption of WGS in the clinic and the potential to positively
impact patient care contributed, at least in part, to the UK100K Project, an
effort by the Department of Health (United Kingdom) to provide high-
coverage WGS for clinical interpretation in 100,000 participants focusing
initially on rare diseases, cancer and infectious disease (www.
genomicsengland.co.uk). Therefore, we sought to investigate the value
of WGS in two cohorts of cancer genetics patients to begin to address
the challenges associated with the identiﬁcation and clinical interpreta-
tion of WGS and potentially pathogenic variants (PPVs) in the genetics
clinic.
Although patients with a family history of cancer are currently eval-
uated with single-gene or gene panel tests, it is not clear whether WGS
will replicate these ﬁndings or potentially increase the rate of identiﬁca-
tion of genetic risk factors. In this study, we modeled a scenario where
WGS replaced gene-speciﬁc testing in 176 BRCA1/2-carriers and 82
non-BRCA patients from our cancer genetics clinics.We sought to exam-
ine whether WGS could be easily and quickly mined to identify PPVsthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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to assess genetic risk for non-cancer conditions.
2. Methods
2.1. Participants
Individuals from the cancer genetics clinics of theUniversity of Texas
Southwestern Medical Center (UTSW) and the Ohio State University
(OSU) cancer genetics programs were recruited to the study following
informed consent approved by the Institutional Review Boards of both
institutions. Only unrelated individuals were included in this study.
Blood samples were obtained and de-identiﬁed. Subsequent genetic re-
sults were not returned to participants.
2.2. Whole-Genome Sequencing and Variant Analysis
WGS of DNA was performed by Complete Genomics Inc. (Mountain
View, CA, USA) as previously described (Drmanac et al., 2010). Se-
quence analysis and variant detectionwere performed by Complete Ge-
nomics Inc., as well. Variant analysis was performed as previously
described (Soyombo et al., 2013); however, variant quality measures
were investigated to determine appropriate quality control parameters
for identifying high-quality PPVs from WGS. To determine the variant
quality score threshold, we measured genotype concordance between
individual-matched WGS from lymphoblast and ﬁbroblast samples
from seven individuals, which are expected to have minimal discrepan-
cies. Genotype concordance was measured using quality score thresh-
olds ranging from 50 to 100 (Supplementary Fig. 1). Single nucleotide
variants (SNVs) with quality scores less than 100 for both alleles were
excluded, resulting in an average SNV genotype concordance rate of
98.88%. Because of the systematically lower concordance and higher
error rate for detecting insertions and deletion (indels) compared to
SNVs, indel concordance was measured using quality scores ranging
from 0 to 300 (Supplementary Fig. 2). Indels with quality scores greater
than 150 were included in the study, resulting in an average genotype
concordance rate of 97.14%, although an average 63.07% of indels origi-
nally identiﬁed by Complete Genomics were excluded.
While numerous aspects of WGS performance are considered and
represented in the variant quality score provided by Complete Geno-
mics, individual quality parameters may improve WGS speciﬁcity and
sensitivity, as are commonly used by other sequencing technologies.
These include, but are not limited to, overall sequence depth, sequence
coverage at variant positions, variant allele fraction, individual read
quality and mapping quality, and read directionality for paired-end
reads. Though these measures were not individually included in the
analysis of WGS from Complete Genomics, the quality score procedure
used here was previously shown to improve concordance to orthogonal
validation by Sanger sequencing (Soyombo et al., 2013). All sequenced
genomesweremapped to the human reference sequence (b37) and an-
alyzed using Complete Genomic's software (version 2.4). A summary of
sequencing statistics (coverage, amount of sequence, total variants and
genome-wide QC measures) is reported per sample in Supplementary
Table 1.
Potentially pathogenic variants (PPVs) were determined primarily by
population frequency using the Exome Variant Server (ESP6500) and a
population of HapMap individuals sequenced by Complete Genomics.
To simplify detection of PPVs, nonsynonymous variants with frequency
less than 1% in both the ESP6500 and HapMap datasets were considered
potentially pathogenic. Loss-of-function (LoF) nonsynonymous variants
were deﬁned as SNVs predicted to create a premature truncation (non-
sense), alter canonical splicing (disrupt), alter the initiating methionine
of the protein (misstart), or alter the ﬁnal stop codon of the transcript
(nonstop). LoF indels included only those resulting in a frameshift and
did not include in-frame deletions and insertions.2.3. Statistical Analyses
All statistical analyses were performed using the R statistical frame-
work. 95% conﬁdence intervals were determined from the binomial
probability. Fisher's exact testwas used to test for signiﬁcant differences
between WGS and published gene-panel sequencing methods (Kurian
et al., 2014).
3. Results
3.1. WGS Conﬁrms Clinically Diagnosed BRCA1/2 Mutations
WGSwas performed on a series of patients from the cancer genetics
clinic that included those found to have BRCA1 (n= 88; Supplementary
Table 2) or BRCA2 (n = 88; Supplementary Table 3) mutations, as well
as those that were not carriers of a BRCA1/2mutation (n= 82; Supple-
mentary Table 4). The genomes of the 176 unrelated BRCA-carriers at
high risk for breast and ovarian cancer were ﬁrst investigated to
determine if WGS conﬁrmed the clinically-diagnosed mutations (Myri-
ad Genetics).
Similar to previous reports (Worthey, 2013), PPVs were deﬁned as
rare (less than 1% frequency in the ESP6500 and HapMap samples se-
quenced using the same technology) nonsynonymous variants. Because
of the variability provided by different computational methods, in silico
predictions of variant pathogenicitywere not used to evaluatemissense
PPVs. Finally, due to technical limitations in detection of copy number
variants (CNVs) and functional annotation of intronic intervening
sequence (IVS) variants, these variants were not considered in our
WGS analysis of PPVs. After applying quality control measures (see
Methods), WGS identiﬁed the majority of clinically-diagnosed BRCA1
and BRCA2 mutations. Of the 75 patients with BRCA1 mutations for
which our method was expected to detect the clinically-diagnosed
PPV, WGS detected 89.3% of the BRCA1mutations; the remaining eight
mutationswere identiﬁed in theWGS data but at lower quality (Supple-
mentary Table 5). Among 88 patients with BRCA2mutations, WGS con-
ﬁrmed 88.6% of the BRCA2 mutations; the remaining ten mutations
were identiﬁed by WGS but again at lower quality (Supplementary
Table 5). In sum,WGS in this cohort detected all BRCA1/2mutations ex-
pected to be identiﬁed by ourWGS approach, although limitations in se-
quence quality prevented conﬁdent reporting of ~12% of BRCA1/2 PPVs.
We expect this result to be a lower-bound, as sequencing technologies
and computational methods continue to improve. Indeed, 16 of 18
(89%) low quality BRCA1/2 variants were indels, and indels were pre-
viously reported to be poorly sequenced using this WGS method
(Drmanac et al., 2010). WGS results are summarized for all BRCA1/2
mutations in Supplementary Tables 6 and 7.
3.2. WGS Detects Cancer-risk PPVs in BRCA1/2 Patients
To model clinical WGS in our patients, we evaluated 163 clinically-
relevant genes (Table 1) to identify PPVs in the BRCA1/2 cohort.
These genes included cancer genes evaluated on commercial cancer-
susceptibility gene panels, genes selected by Dorschner et al. (2013) as
genes that might impact reproductive decision making (e.g. carrier-
status reporting) as well as genes initially recommended for reporting
by ACMG (Green et al., 2013). In total, the initial gene panel represented
135 dominant, 24 recessive and 4 X-linked disease-associated genes.
WGS identiﬁed 1207 PPVs in the 176 patient genomes with BRCA
mutations, representing 695 unique variants. Of these, most were mis-
sense variants and 46.33% of all PPVs were novel and not present in
the ESP6500 database (Supplementary Table 8). On average,WGS iden-
tiﬁed 6.8 and 6.9 PPVs per patient in the BRCA1- and BRCA2-carrier co-
horts, respectively (Fig. 1A). Among the 163 genes, the number of
PPVs per gene varied greatly (Supplementary Tables 9 and 10). Similar
gene variance results were obtained for BRCA1- or BRCA2-carrier co-
horts evaluated separately (Supplementary Tables 11 and 12). As
Table 1
163 disease-gene panel.
Dominant Dominant (cont.) Dominant (cont.) Recessive X-linked
ACTA2a HIP1 PROC ATP7B DMD
ACTC1a HIP1R PROS1 BCHE EMD
ACVRL1 HMBS PRSS1 BLM GLAa
APCa HOXB1 PTCH1 CASQ2 OTC
APOBa HOXB13 PTENa CFTR –
ATM HTT RAD50 COQ2 –
ATR JAK2 RAD51 COQ9 –
BAP1 KCNE1 RAD51C CPT2 –
BARD1 KCNE2 RAD51D F5 –
BMPR1A KCNE3 RAS GAA –
BRCA1a KCNH1 RB1a HAMP –
BRCA2a KCNH2a RBBP8 HFE –
BRIP1 KCNJ2 RBM20 HFE2 –
CACNA1C KCNQ1a RETa IDUA –
CACNA1Sa KDR RYR1a INPP5B –
CACNB2 KIT RYR2a LDLRAP1 –
CDC73 LDLRa SCN1B PAH –
CDH1 LMNAa SCN3B PCBD1 –
CDK4 MEN1a SCN5Aa PTS –
CDKN1A MET SDHAF2a QDPR –
CDKN2A MITF SDHBa SERPINA1 –
CDKN2B MLH1a SDHCa SLC25A13 –
CHEK1 MLH3 SDHDa SLC37A4 –
CHEK2 MRE11A SERPINC1 SLC7A9 –
CNBP MSH2a SGCD – –
COL3A1a MSH6a SMAD3a – –
CREBBP MUTYHa SMAD4 – –
DMPK MYBPC3a SMARCB1 – –
DSC2a MYH11a SMO – –
DSG2a MYH7a STK11a – –
DSPa MYL2a TGFB3 – –
EGFR MYL3a TGFBR1a – –
ELAC2 MYLKa TGFBR2a – –
ENG NBN TMEM43a – –
EPCAM NF1 TNNI3a – –
FAM175A/Abraxas NF2a TNNT2a – –
FBN1a NTRK1a TP53a – –
FH PALB2 TP53BP1 – –
FLCN PCSK9a TPM1a – –
GALNT12 PDGFRA TSC1a – –
GCH1 PKP2a TSC2a – –
GEN1 PLN VHLa – –
GPD1L PMS2a WT1a – –
GREM1 PRKAG2a XRCC2 – –
HCN4 PRKAR1A XRCC3 – –
Bold = cancer-associated genes.
a ACMG genes.
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PPVs (see Methods), the number of variants decreased dramatically.
This indicates that a majority of nonsynonymous PPVs in the cancer ge-
netics clinic will be classiﬁed as variants of unknown signiﬁcance (VUS),
reinforcing the challenge of expanding the scope of clinical WGS
(Biesecker, 2012); namely, the interpretation of novel nonsynonymous
(missense) PPVs.
To begin to address this, we reviewed each of the 695 PPVs for pub-
lished evidence of pathogenicity or associationwith disease. Inmany in-
dividuals for whom family members were recruited, as has been found
by Johnston et al. and others in their evaluation of next generation se-
quencing (Johnston et al., 2012), we found no evidence for co-
segregation of the variant with disease or found inconsistencies in
their association with disease in the literature. For example, WGS iden-
tiﬁed a patientwith amissense variant (p.Asn1978Ser) in CREBBP previ-
ously reported as pathogenic and diagnostic for autosomal dominant
Rubenstein Taybi Syndrome (RTS) (Bartsch et al., 2005; Roelfsema and
Peters, 2007). Subsequently, four additional individuals in our BRCA1/2
cohort with the same variant were identiﬁed and conﬁrmed by Sanger
sequencing. Detailed family history aswell asDNA samples from several
family members of one index patient with this CREBBP variant were
available, and the patient and her family members that carried thevariant had no symptoms consistent with a RTS diagnosis (Supplemen-
tary Fig. 3). In a second example, WGS identiﬁed a missense variant
(p.Asn29Ile) in PRSS1 considered pathogenic by clinical laboratories
(e.g. Ambry Genetics) as it has previously been associated with heredi-
tary pancreatitis and subsequent pancreatic cancer (Whitcomb, 2013;
Sanchez-Ramirez et al., 2012; Gorry et al., 1997). A total of nine individ-
uals were identiﬁedwith this same variant and conﬁrmed by Sanger se-
quencing, and no PRSS1-variant carrying individual reported pancreatic
problems. Further investigation of these patients' pedigrees showed
that one individual's family history supported the WGS result: the
patient's father, whowas unavailable for testing but presumed to trans-
mit the variant (hermother lacked the PRSS1 variant) died of pancreatic
cancer at age 53 (Supplementary Fig. 4). While WGS has potential to
expand the breadth of disease risk reported to individual patients, it is
evident that clinical interpretation of WGS results, particularly for mis-
sense variants, requires detailed medical histories and results from ex-
tended family members to have conﬁdent diagnoses for appropriate
genetic counseling. Importantly, previously reported disease associa-
tions should be met with caution, not considered to be equivalent to
causation, and be interpreted in light of available familymedical history.
3.3. Comparison of WGS Results in Two Cancer Genetics Clinic Cohorts
Because clinical WGS is likely to report an overwhelming number of
VUSs (Domchek et al., 2013; Yorczyk et al., 2014), we sought to evaluate
the frequency of PPVs in individual genes in different clinic populations.
We compared the WGS results from the BRCA1/2-carrier cohort (n =
176) to the non-BRCA cancer genetics clinic cohort (n = 82) using a
“gene variance” analysis. The two cohorts served as reciprocal controls
since themajority of the cancers present in the BRCA1/2 cohort presum-
ably resulted from the patients' pathogenic BRCA1/2mutations, while
the non-BRCA cohort had either negative tests for BRCA1/2mutations
or cancers not associated with BRCA1/2. Because PPVs were selected
with less than 1% allele frequency, heterozygous individuals are expect-
ed to occur in less than 2% of patients in the BRCA1/2 “control” popula-
tion. Using this method, we concluded that genes reported as harboring
PPVs in less than 2% of this cohort are “clinically interpretable” using
WGS and not likely to result in numerous false-positive PPVs reported
to patients. As such, many “clinically interpretable” genes had no PPVs
in either cohort.
This “gene variance” analysis allowed us to calculate and visualize
the percentage of clinically interpretable genes (excluding BRCA1 and
BRCA2), deﬁned as genes with less than 2% of individuals carrying
PPVs in the “control” BRCA1/2 cohort, using different approaches to de-
ﬁne PPVs. Including all nonsynonymous PPVs, only 52.8% of genes were
considered clinically interpretable (Fig. 1B). Interestingly, 6% and 20% of
the non-BRCA cohort had PPVs in BRCA1 and BRCA2, respectively, and
both genes were among the most variable genes we investigated. We
note that these PPVs were previously deemed benign with clinical test-
ing (Myriad Genetics) in patients for whom their cancer could have
been associated with BRCA1/2 mutations. Additionally, while 67.3%
and 66.2% of PPVs in the BRCA1 and BRCA2 genes in the BRCA1/2 cohort,
respectively, were predicted LoF variants, none of the four BRCA1 or 16
BRCA2 variants in the non-BRCA cohort were predicted LoF variants.
These results highlight the challenge, even for commonly-tested
genes, of clinical interpretation for rare missense variants detected by
WGS. It also underscores the increased speciﬁcity of clinical WGS by in-
vestigating LoF variants, the majority of which are likely to have similar
functional consequences regardless of the genetic heterogeneity of indi-
vidual genes. The lack of clinical speciﬁcity among missense PPVs was
evident, as there was a correlation of PPV frequency with coding region
size in the BRCA1/2 (r2 = 0.61) and non-BRCA (r2 = 0.5217) cohorts
(Supplemental Fig. 5A, C). When restricting the analysis to LoF PPVs
the correlation with size was lost, suggesting LoF PPVs may be more as-
sociated with the patient's clinical presentation than the gene's back-
ground mutation rate (Supplemental Fig. 5B, D).
Fig. 1. Analysis of potentially pathogenic variants (PPVs) in 163 disease genes. (A) Histogram distribution of the number of PPVs from WGS analysis of 163 genes is shown. Each clinic
cohort is shown, including patients with either clinically-diagnosed BRCA1mutations (blue), BRCA2mutations (orange) or without BRCA1/2mutations (black). (B, C) “Gene variance
plot” of carrier burden (average number of PPVs per individual) for (B) all PPVs in the 163 disease-gene panel or (C) loss-of-function (LoF) PPVs in the 163 disease-gene panel. Genes
harboring PPVs in at least 2% of the BRCA1/2 cohort are shown in the shaded region. Those genes not in the shaded region were considered “clinically interpretable” by WGS. One dot
can represent several genes. For instance the black dot at zero in both populations represents many genes lacking PPVs in both cohorts. Genes shown in red are those that harbored can-
cer-risk PPVs in patients, also listed in Tables 2 and 3.
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genes increased to 97.5%, and PPVs clinically diagnosed as pathogenic
mutations by Myriad Genetics in the BRCA1 and BRCA2 genes were
now speciﬁc to the BRCA1/2 cohort (Fig. 1C). Restricting clinical inter-
pretation to LoF variants has three advantages. First, LoF variants are
more likely to be associated with human disease and may be enriched
for diagnostic variants compared to other nonsynonymous variants.
Second, restricting results to LoF variants greatly reduces the number
of PPVs returned to patients andmay simplify interpretation of reported
variants, for both the clinician and patient. However, we recognize that
the increase in the percent interpretable genes is due mostly to the in-
crease in the number of genes without PPVs in both cohorts and that
thismay also increase the false-negative rate of our simpliﬁed approach.
Although this is reasonable in the research setting, false-negative test
results in the clinical setting are of little beneﬁt andmethods are needed
to improve the sensitivity and speciﬁcity of WGS for clinical diagnosis.And last, although a frequency less than 1% is a commonly used thresh-
old for deﬁning PPVs, rare variants are more likely to be population
speciﬁc and a universal 1% threshold may not be appropriate for all
ethnicities. However, we did investigate alternative frequency thresh-
olds and found that this approach performed best in our population
(Supplementary Table 13). Even still, some genes reported a high fre-
quency of LoF PPVs in both populations. GEN1 harbored a single novel
deletion resulting in a predicted frame-shift variant that was frequently
present in both cohorts. This variant is likely a sequencing artifact be-
cause of its frequency in both populations and our inability to conﬁrm
it by Sanger sequencing (data not shown). This may foreshadow future
difﬁculties for clinical interpretation of GEN1 LoF variants (indels) by
next-generation sequencing methods.
After excludingGEN1 from the analysis, theWGSdata identiﬁed six in-
dividuals in the BRCA1/2 cohort with LoF PPVs in four dominant cancer-
associated genes, in addition to their clinically diagnosed BRCA1/2
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dicted cancer riskmutations in BRCA1/2-carrier patients thatweremissed
using standard clinical methods. Interestingly, one individual (BRCA2.65)
with a history ofmelanoma had a nonsense variant in CDKN2B (p.Glu35*)
that, to our knowledge, is theﬁrst reported individualwith a germline LoF
variant in CDKN2B (also knownas p15Ink4b); no germline CDKN2B LoF var-
iants are reported fromexome sequencing of 6503 individuals (ESP6500).
The knowledge that patients carry additional deleterious cancer-
predisposing mutations would be of deﬁnite use for counseling and
then screening of the patient's family members.
Analysis of LoF PPVs in genes that cause diseases other than cancer
identiﬁed genetic risks in 19 of the 176 (10.8%) BRCA1/2-carriers
(Supplementary Table 14). For example,WGS identiﬁed a heterozygous
nonsense variant (p.Gly542*) in the CFTR gene. Although homozygous
or compound heterozygous mutations in the CFTR gene cause cystic ﬁ-
brosis, there is little evidence to date that the knowledge would be
used for anything other than potentially prenatal counseling. As expect-
ed,WGS has the potential to provide additional genetic risk assessments
for conditions other than the primary diagnosis (cancer), and these re-
sults will require genetic counseling.
3.4. WGS Detects Cancer-risk PPVs in Non-BRCA Patients
We next asked whether WGS provided added value in the cohort of
82 unrelated non-BRCApatients (Supplementary Table 4). This cohort is
representative of our clinic census with the exception of removing
BRCA1/2-carriers individuals for the ﬁrst cohort. Using the same model
as described above, the cohort averaged 6.4 PPVs in the selected 163
genes (Fig. 1A; Supplementary Tables 15 and 16), and we subsequently
focused only on LoF PPVs, which averaged 0.4 LoF PPVs per individual
(Fig. 1C). Excluding GEN1, WGS identiﬁed LoF PPVs in 14 genes in 18
of 82 (22%) non-BRCA individuals. The LoF variants represented only
6% of all PPVs identiﬁed by WGS in the 163 genes. Importantly, of the
13 individuals with LoF PPVs in cancer-associated genes, 11 were in
genes implicated in the individual's primary cancer diagnosis and two
provided a likely genetic diagnosis based on family history (Table 3).
WGS also detected LoF PPVs in cancer genes beyond tests performed
as standard of care for this population. Two individuals (UTSW9 and
UTSW36) harbored nonsense mutations in PALB2, which has recently
been reported to result in an elevated risk for breast cancer similar to
BRCA2 mutations (Antoniou et al., 2014). A nonsense mutation in
RAD51Cwas identiﬁed in another individual (UTSW13) who was origi-
nally tested in the clinic for an FHmutation (WGS identiﬁed this muta-
tion aswell). Again, this illustrates the potential ofWGS andmulti-gene
panels to identify co-occurring cancer genemutations (e.g. RAD51C and
FH) that pose genetic risks (breast/ovarian cancer) beyond the patient'sTable 2
Potentially pathogenic LoF variants in cancer-associated genes in BRCA1/2-carriers.
Patient Gene Varianta Patient cancer historyb
Discovered cancer gene mutations (163 disease-gene panel)c
BRCA1.60 CHEK2 c.573+1GNA Breast-47, 49
BRCA1.61 ATM p.Glu2290⁎ Unaffected-24
BRCA2.7 RAD50 c.3GNA Breast-49
BRCA2.13 ATM p.Glu1978⁎ Breast-28, 39, 55; Skin-49
BRCA2.65 CDKN2B p.Glu35⁎ Melanoma-50
BRCA2.93 CHEK2 p.Gln20⁎ Breast-37, 61; Ovarian-56
Discovered cancer gene mutations (ClinVar)c
BRCA1.48 ERCC3 p.Arg109⁎ Breast-39; Skin-61, 66
BRCA1.73 DLEC1 c.2436-2ANG Breast-32
BRCA1.74 FANCC p.Arg548⁎ Breast-42, 53, 55
a The one indel variant is shown in bold.
b Age at diagnosis or current age of unaffected.
c Discovered variants were identiﬁed byWGS and not tested by clinical genetic testing
performed as standard of care.
⁎ Stop gain mutation.primary diagnosis (leiomyoma). WGS is an unbiased approach to iden-
tify unanticipated risk factors, and the entirety of genetic information
may prove useful as additional disease-causing genes are discovered.
WGS in the clinical setting will require extensive pre-test genetic
counseling.
Because several of the non-BRCA-carrier patients werewithout a ge-
netic diagnosis, we expanded ourWGS analysis to include all genes an-
notated in the ClinVar database (a public collection of 3209 genes
associated with human disease; accessed June 2, 2014). However, as
the number of genes investigated by WGS increased, so too did the
number of PPVs reported to patients, which averaged 111 PPVs per in-
dividual. Using the same variance analysis as performed for the 163
disease-genes, only 60.0% of ClinVar genes met our criteria for being
clinically interpretable, and this improved to 98.6% when restricting
the analysis to LoF PPVs (Fig. 2A and B) and averaged 7.8 LoF PPVs per
individual.
To further assess the effect of restricting PPVs to increase speciﬁcity,
we focused on LoF SNVs, which slightly improved the percent of clini-
cally interpretable genes to 99.6% (Fig. 2C) and averaged only 1.9 LoF
SNV PPVs per individual. Only nine of the 82 (11%) non-BRCA individ-
uals had no LoF SNV PPVs in any ClinVar gene. Of the 121 ClinVar
genes harboring LoF SNV PPVs, 48 (39.7%) were associated with au-
tosomal dominant diseases (Supplementary Table 17) and 73 (60.3%)
were associated with recessive or X-linked diseases (Supplementary
Table 18). Of the 131 LoF SNV PPVs, 78 (59.5%) variants in 58 (70.7%) in-
dividuals were novel.
Focusing speciﬁcally on known cancer-associated genes in the
ClinVar database, WGS results were compared to our clinical testing
performed as standard of care in the cancer genetics clinic. In addition
to conﬁrming mutations diagnosed with standard clinical testing, vari-
ant analysis of ClinVar genes identiﬁed LoF SNV PPVs in previously un-
suspected cancer-associated genes that were not considered as part of
standard clinical care (Tables 2 and 3). Of those listed, ERCC3, FANCA
and FANCM LoF variants are good candidates for further research as po-
tential cancer-susceptibility mutations as the normal functions of their
gene products are in DNA repair pathways. Note that LoF PPVs in
ClinVar genes, even if they alter DNA repair pathways, are not necessar-
ily high risk cancer susceptibility mutations. More clinical data is
required to quantify risk as was recently done for PALB2 LoF PPVs
(Antoniou et al., 2014). This highlights the potential for WGS to identify
putative cancer risk variants in patients and ultimately increase diagno-
ses for individuals undergoing genetic testing.
ERCC3 and FANCC LoF variants were also discovered as additional
mutations in the BRCA1/2 cohort after analysis of ClinVar gene muta-
tions (Fig. 2C, Table 2). ExpandingWGS to ClinVar genes also identiﬁed
a LoF mutation in the tumor suppressor gene DLEC1 in a BRCA1-mutant
patient (BRCA1.73); the function of the encoded DLEC1 protein is not
well deﬁned but has been found to be lost in breast cancer. The DLEC1
acronym stands for “deleted in lung and esophageal cancer” as its ex-
pression is lost in these two cancers (and other cancers including pros-
tate and breast) due to somaticmutations or gene silencing (Daigo et al.,
1999; Yuan et al., 2003a, 2003b). We are not aware of earlier reports of
DLEC1 germline mutations associating with familial cancer, illustrating
the research value of WGS in the clinic.
4. Discussion
The decreasing cost and potential to provide a more comprehensive
genetic risk assessment than current targeted methods makes WGS an
attractive tool for genetic screening in patients with a family history of
disease. For patients in the cancer genetics clinic, WGS may provide
new opportunities to better understand their genetic risk for cancer,
aswell as other (non-cancer) conditions. Therefore, wemodeled clinical
WGS by performing WGS in patients with and without clinically-
conﬁrmed BRCA1/2 mutations. This allowed us to begin to address im-
portant questions regarding WGS in the cancer clinic. Particularly, we
Table 3
WGS identiﬁes potentially pathogenic LoF variants in cancer-associated genes in the non-BRCA cohort.
Patient Gene Variantd Cancer historya Family cancer history
Conﬁrmed cancer gene mutationsb
UTSW3 TP53 p.Arg196⁎ Adrenocortical-1 Breast, lung, prostate
UTSW12 APC p.Asp170Valfs⁎4 Colon polyposis-51 None
UTSW13 FH p.Gln185Leufs⁎18 Leiomyoma-33 Breast, colon, leiomyoma, RCC
UTSW16 APC p.Arg1920Glufs⁎50 Colon polyposis-53 None
UTSW31 MSH6 p.Phe569Hisfs⁎7 Colon-52 Endometrial
UTSW32 MSH6 p.Arg911⁎ Colon-40 None
UTSW38 FH p.Gln185Leufs⁎18 Papillary RCC-48 Breast, leiomyoma
UTSW44 MSH2 p.Arg389⁎ Unaffected-27 Colon
UTSW53 MSH6 p.Lys1013Ilefs⁎3 Unaffected-30 Colon
UTSW55 APC p.Glu1309Aspfs⁎4 Colon polyposis-26 Colon
UTSW78 ATM p.Val835Serfs⁎7 Breast-54, 56 Brain, breast, colon, lung, prostate
UTSW78 RAD50 p.Thr109Asnfs⁎20 Breast-54, 56 Brain, breast, colon, lung, prostate
Discovered cancer gene mutations (163 disease-gene panel)c
UTSW9 PALB2 p.Tyr1183⁎ DLCBL-41 Breast, lung, multiple myeloma, RCC
UTSW13 RAD51C p.ArgR193⁎ Leiomyoma-33 Breast, colon, leiomyoma, RCC
UTSW36 PALB2 p.Glu27⁎ Vulvar-64; Breast-68 Breast, pancreatic, prostate, stomach
Discovered cancer gene mutations (ClinVar)c
UTSW22 FANCM p.Gln1701⁎ Breast-48, 56; Pancreatic-58 Breast, colon, ovarian, prostate, stomach
UTSW51 FANCM p.Gln1701⁎ Unaffected-40 Brain, lung
UTSW76 ERCC3 p.Arg109⁎ Breast-47 Breast, colon, endometrial, prostate, thyroid
UTSW82 FANCA p.Glu288⁎ Breast-61; Renal oncocytoma-66 Breast, colon, prostate
Abbreviations: DLCBL, diffuse large B-cell lymphoma; RCC, renal cell carcinoma.
a Age at diagnosis or current age of unaffected.
b Conﬁrmed variants were previously identiﬁed by clinical genetic testing performed as standard of care.
c Discovered variants were identiﬁed by WGS and not tested by clinical genetic testing performed as standard of care.
d Indel variants are shown in bold.
⁎ Premature stop gain.
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potential clinical implications of individual variants in coding regions
of known disease genes would be less burdensome to the patient and
clinician and whether WGS provided added value beyond physician-
ordered targeted gene or multi-gene panel testing performed as stan-
dard of care for our patients.
Initial investigation of the frequency and co-occurrence of PPVs from
a limited panel of 163 disease genes in the BRCA1/2-carrier cohort indi-
cated that the majority of nonsynonymous PPVs in the cancer genetics
clinic will be novel VUSs (not present in the ESP6500 database). Fur-
thermore, our observation of the limited phenotypic effects of previous-
ly reported pathogenic missense variants in several genes, as illustrated
by the examples of CREBBP and PRSS1, reinforces how WGS coupled
with patient phenotyping will improve the clinical interpretation of ge-
netic diagnoses. That previous estimates of risk for the CREBBP and
PRSS1 variants were not predictive in our study cohorts illustrates that
clinical-risk prediction for missense variants is frequently in need of ad-
ditional patient data for conﬁdent associationwith disease in individual
patients.
Additional methods based on computational predictions of deleteri-
ousness have been proposed to improve detection of potential disease-
causing PPVs, though their clinical use remains unclear. The Combined
Annotation-Dependent Depletion (CADD) score represents a summary
statistic incorporating multiple predictive methods (Kircher et al.,
2014). As expected, a majority of clinically diagnostic LoF PPVs had
very high CADD scores; however, only a small proportion of missense
PPVs had similarly high CADD scores (Supplemental Fig. 6A). As well,
the variability of individual variant CADD scores within a variant class
(missense, misstart, etc.) increased as WGS analysis was expanded to
all ClinVar genes (Supplemental Fig. 6B). It remains unclear whether
CADD scores, or other computational predictions of deleteriousness,
will improve clinical interpretation of missense PPVs.
Because of the overwhelming frequency of novelmissense PPVs and
the difﬁculty of associating speciﬁc PPVs with disease in the published
literature, we restricted our analysis to LoF PPVs, which represented a
small minority of the PPVs and are predicted to be enriched forpathogenic variants. Limiting reporting to LoF variants in the clinic
may assuage some of the fears clinicians feel when contemplating the
new era of next-generation sequencing, namely the functional interpre-
tation of VUSs. A similar approach was recently used to investigate the
diagnostic rate of WGS in patients with intellectual disability (Gilissen
et al., 2014). WGS was performed using the same method reported
here (Complete Genomics, Inc.) in 50 patients and focused speciﬁcally
on de novo variants, which required sequencing of parents aswell as pa-
tients. WGS diagnostic yield and genetic diagnoses were increased if
analysis was restricted to LoF sequence variants.
Finally, we expanded WGS analysis to include all human disease-
causing genes annotated in the ClinVar database. This potentially repre-
sents the largest collection of genes relevant to human health and dis-
ease. As expected, expanding WGS analysis increased the number of
LoF PPVs; therefore, we further restricted the WGS analysis to LoF
SNVs. In total, WGS provided likely genetic cancer risk PPVs in 20.7%
[95% CI: 12.6–31.1%] of non-BRCA1/2 clinic patients. A recent report
using targeted gene panel testing provided similar cancer risk PPVs in
10.6% [95% CI: 6.1–16.9%] of non-BRCA1/2 patients (Kurian et al.,
2014). Therefore, WGS may provide genetic risk predictions for more
patients than targeted gene panel testing (p = 0.048), though we
expect that signiﬁcant research efforts in larger patient cohorts will be
needed before clinical WGS is widely adopted. We do note that
restricting analyses to LoF SNVs (as for ClinVar genes) is very conserva-
tive and that such an approach would have failed to identify likely can-
cer risk PPVs in our initial analysis of 163 genes. Comprehensive WGS
analysis methods are likely to improve as clinical WGS becomes more
widely accepted, and this may require a concerted effort to integrate
multi-center WGS results with detailed clinical data from large patient
cohorts.
Furthermore, while restricting the analysis to LoF variants for re-
search is feasible, there remains the challenge of false-negatives in
the clinical setting. These false-negatives come not only from the
conservative interpretation of variants but also from the technical
limitations of next-generation sequencing platforms. The use of mul-
tiple technologies to supplement genome sequencing, such as
Fig. 2. Analysis of PPVs identiﬁed byWGS in ClinVar genes. “Gene variance plot” of carrier
burden (average number of PPVs per individual) for (A) all PPVs in ClinVar genes, (B) loss-
of-function (LoF) PPVs in ClinVar genes or (C) only LoF single nucleotide variant (SNV)
PPVs for each gene annotated in the ClinVar database (3209 genes). Genes harboring
PPVs in at least 2% of the BRCA1/2 cohort are shown in the shaded region. Those genes
not in the shaded region were considered “clinically interpretable” by WGS. One dot can
represent several genes. Genes shown in red are those that harbored cancer-risk PPVs in
patients, also listed in Tables 2 and 3.
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ing technologies and software for variant analysis overcome these
challenges.There are other major challenges involved in translating WGS into
the clinic, including questions of mutation penetrance, better under-
standing of the genes about which we understand little, and how to
counsel patients who test negative or positive for an identiﬁed familial
mutation in one of the less well understood genes (CHEK2, PALB2 or
RAD51C are good examples of this). Recently we documented that
even clinical laboratories are not interpreting the signiﬁcance of vari-
ants consistently (Yorczyk et al., 2014). This increases the urgency for
information sharing of variants and their classiﬁcations. The more
patients we evaluatewith detailed and precise family history, the better
wewill understand the clinical signiﬁcance of individual genes and, pos-
sibly, speciﬁc gene mutations. We encourage all clinicians and re-
searchers to use consents that facilitate wide sharing of de-identiﬁed
data and to submit the results of their studies to public repositories
like dbGaP. WGS reported here will be made available through the
NCBI dbGaP repository.
Finally, though WGS was performed in these patients, we limited
our analysis to the protein-coding exome to facilitate interpretation of
nonsynonymous variants. In addition to better clinical interpretation
of nonsynonymous (and other) variants, technical improvements will
be required to comprehensively detect variants other than SNVs. The
overwhelming false-positive rate and lower quality and conﬁdence for
detecting insertions and deletions may contribute signiﬁcantly to the
lack of a better diagnosis rate using WGS. Though currently whole-
exome sequencingmay provemore cost-effective, careful consideration
should be paid to understanding the cost–beneﬁt of both methods as
technologies continue to improve and sequencing costs decrease, in-
cluding aspects of sequence uniformity and completeness aswell as im-
provements in variant detection (Biesecker and Green, 2014).
The results from our study highlight the ongoing discussion as to the
appropriateness and use of WGS to balance our research goals to
improve future patient care and risk awarenesswith the goal of improv-
ing our current patients' overall health and well-being (Burke and
Dimmock, 2014). Proponents of clinical WGS highlight the potential to
identify not only genetic risks for the patient's primary diagnosis but
also risks for other diseases or conditions that may beneﬁt the patient,
such as late-onset diseases or disease risk that may affect reproductive
decision-making or family planning. However, contradictory opinions
often revolve around the interpretation of sequence results and wheth-
er ﬁndings unrelated to the current clinical presentation should be
returned to patients. While not discussed here, these questions should
be addressed for WGS to have the most beneﬁt for current and future
patients.
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